XML 41 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Deficiency
6 Months Ended
Jun. 30, 2013
Stockholders Deficiency  
Note 7 - Stockholders' Deficiency

Common Stock

 

During the six months ended June 30, 2013, pursuant to a private placement offering of units that commenced on October 4, 2012 (the “Private Placement”), the Company received an aggregate of $3,501,975 of proceeds related to the sale of 3,501,975 units at a price of $1.00 per unit. The aggregate amount includes $500,000, which was received from an officer, and $850,002, which was received during the fourth quarter of 2012 and classified as restricted cash as of December 31, 2012. Each unit consists of (i) one share of the Company’s common stock and (ii) a five-year warrant to purchase three shares of the Company’s common stock at an exercise price of $0.25 per share, such that warrants to purchase an aggregate of 10,505,925 shares of common stock were issued. Substantially all of the proceeds from the sale of the units were used by the Company to satisfy all of its obligations under the convertible notes and notes (see Notes 5 and 6). In connection with the Private Placement, an officer has entered into repurchase agreements with certain purchasers of units, pursuant to which he has agreed to repurchase, subject to certain conditions, one-half of these holder’s units at a purchase price of $1.00 per unit if the closing price of the Common Stock is less than $0.25 on five consecutive trading days at any time within one year of February 1, 2013. Cape Bear, which holds a substantial equity position in the Company, also entered into repurchase agreements with certain purchasers, other than the officer, that are substantially similar to the officer’s agreements, except that Cape Bear’s obligations are secured by a lien over certain real estate.

 

On March 13, 2013, the Company exchanged $761,000 of notes payable and other advances – related parties and $72,000 of accounts payable to a related party into an aggregate of 833,000 units at a price of $1.00 per unit. Each unit consists of (i) one share of the Company’s common stock, and (ii) a five-year warrant to purchase two and three-quarters shares of the Company’s common stock at an exercise price of $0.25 per share (such that warrants to purchase an aggregate of 2,290,750 shares of common stock were issued). The $3,625,900 aggregate fair value of the securities issued ($2,639,700 related to the warrants and $986,200 related to the common stock) was credited to equity at conversion. The Company recorded a $2,792,900 extinguishment loss which represents the incremental fair value of the securities issued as compared to the carrying value of the liabilities.

 

Series B Preferred Stock

 

On January 1, 2013, the Company issued 27,630 shares of Series B Convertible Preferred Stock valued at $261,084, representing approximately $0.66 in value per share of Series B Preferred Stock outstanding to the Series B Convertible Preferred Stockholders as payment in kind for dividends (the “2013 Series B Dividend”). In connection with the 2013 Series B Dividend, the Company recognized a beneficial conversion feature of $202,305 during the six months ended June 30, 2013, which represents the difference between the commitment date value of the shares and the effective conversion price. In connection with the outstanding preferred stock, during the three and six months ended June 30, 2013, the Company recorded $69,840 and $139,689 as contractual dividends, respectively, and recorded $65,271 and $130,542 during the three and six months ended June 30, 2012, respectively. As of December 31, 2012, February 1, 2013, March 13, 2013 and April 11, 2013, Series B holders were entitled to convert into 5.00, 7.61, 8.07 and 8.14 shares, respectively, of the Company’s common stock for each share of Series B Preferred Stock due to the anti-dilution provision. The anti-dilution provision represents a contingent beneficial conversion feature.  As of June 30, 2013, an incremental 1,326,700 shares of common stock are issuable at conversion of the Series B Convertible Preferred Stock as compared to the original terms.   Using the commitment date common stock price in effect, the commitment date value of the incremental shares is $3,348,975. However, recognition of beneficial conversion features is limited to the aggregate gross proceeds allocated to the preferred stock of $3,199,689 (422,315 shares of Series B Convertible Preferred Stock times $9.45 per share less the proceeds allocated to the warrants of $791,188) less the $1,666,967 beneficial conversion feature already recognized on the original 365,265 shares of Series B Preferred Stock (prior to the issuance of additional shares as payment-in-kind in lieu of cash dividends) and the $202,305 recognized related to the 2013 Series B Dividend. Due to these limitations, a beneficial conversion feature of $0 and $1,330,417 related to the incremental shares was recognized during the three and six months ended June 30, 2013, respectively.

 

Series C Preferred Stock

 

On February 13, 2013, the Company received a Notice of Redemption of Series C Preferred Stock. As a result of the Convertible Notes coming due and not being paid on December 31, 2012, the Company accelerated the accretion rate of the deemed dividend on the Redeemable Preferred Stock – Series C and reclassified the Redeemable Preferred Stock – Series C from temporary equity to current liabilities. The Company recorded Series C deemed dividends of $92,916 and $185,832 during the three and six months ended June 30, 2012, respectively. As of December 31, 2012, the discount associated with the Series C Preferred Stock was fully amortized.

 

Stock Options

 

In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:

 

    For The Three Months Ended   For The Six Months Ended
    June 30,   June 30,
    2013   2012   2013   2012
                 
Risk free interest rate   1.50%   n/a   1.13% to 1.50%   1.04%
Dividend yield   0.00%   n/a   0.00%   0.00%
Expected volatility   175.0%   n/a   166.0% to 175.0%   172.2%
Expectd life in years   6.00   n/a   6.00   6.00

 

The weighted average fair value of the stock options granted during the three and six months ended June 30, 2013 was $1.45 and $1.57 per share, respectively. The weighted average fair value of the stock options granted during the six months ended June 30, 2012 was $6.99 per share.  There were no stock options granted during the three months ended June 30, 2012.

 

On February 15, 2013, the Company granted options to employees to purchase an aggregate of 330,500 shares of common stock under the 2009 Plan at an exercise price of $1.60 per share for an aggregate grant date value of $395,041. The options vest over a three year period and have a term of ten years.

 

On June 19, 2013, the Company granted an option to a director to purchase 100,000 shares of common stock under the 2009 Plan at an exercise price of $1.45 per share for a grant date value of $109,600.  The option vests over a three year period and has a term of ten years.

 

Stock-based compensation expense related to stock options was recorded in the condensed consolidated statements of operations as a component of selling, general and administrative expenses and totaled $13,799 and $326,243 for the three and six months ended June 30, 2013, respectively, and $290,221 and $549,630 for the three and six months ended June 30, 2012, respectively.  As of June 30, 2013, stock-based compensation expense related to stock options of $1,987,548 remains unamortized, including $1,095,979 which is being amortized over the weighted average remaining period of 2.1 years.  The remaining $891,569 is related to a performance based option where vesting is currently deemed to be improbable and no amount is being amortized.

 

A summary of the stock option activity during the six months ended June 30, 2013 is presented below:

 

    Number     Weighted Average     Weighted Average Remaining        
    of     Exercise     Life     Intrinsic  
    Options     Price     In Years     Value  
                         
Outstanding, January 1, 2013     2,183,899     $ 3.42              
Granted     430,500       1.57              
Exercised     -       -              
Forfeited     (378,749 )     4.40              
Outstanding, June 30, 2013     2,235,650     $ 2.89       5.7     $ 143,937  
                                 
Exercisable, June 30, 2013     1,183,483     $ 2.67       4.5     $ 141,733  

 

The following table presents information related to stock options at June 30, 2013:

 

    Options Outstanding   Options Exercisable
    Weighted       Weighted   Weighted    
Range of   Average   Outstanding   Average   Average   Exercisable
Exercise   Exercise   Number of   Exercise   Remaining Life   Number of
Price   Price   Options   Price   In Years   Options
                     
 $0.80 - $2.20    $         1.57             906,400    $         1.58                            2.2             485,900
 $2.21 - $3.80               3.21             868,250               2.96                            5.3             500,917
 $3.81 - $6.99               4.88             461,000               4.65                            7.9             196,666
     $         2.89          2,235,650    $         2.67                            4.5          1,183,483

 

Warrants

 

In applying the Black-Scholes option pricing model to stock warrants granted, the Company used the following weighted average assumptions:

 

    For The Three Months Ended   For The Six Months Ended
    June 30,   June 30,
    2013   2012   2013   2012
                 
Risk free interest rate   0.74%   n/a   0.87%   n/a
Dividend yield   0.00%   n/a   0.00%   n/a
Expected volatility   166.0%   n/a   164.3%   n/a
Expectd life in years   5.00   n/a   5.00   n/a

 

The weighted average fair value of the stock warrants granted during the three and six months ended June 30, 2013 was $0.71 and $1.36 per share, respectively.  There were no warrants granted during the three and six months ended June 30, 2012.

 

On February 15, 2013, the Company granted vested five-year warrants to purchase an aggregate of 408,345 shares of common stock at an exercise price of $1.00 per share to investors who purchased shares in private placements at $4.50 per share during 2012. The warrants had an issuance date fair value of $487,200 which was expensed immediately.

 

See Note 7 – Stockholders’ Deficiency – Common Stock for details regarding warrants granted in connection with the Private Placement and the conversion of related party notes payable, other advances and accounts payable into equity.

 

During the six months ended June 30, 2013, the Company issued an aggregate of 9,734,747 shares of common stock to several holders of warrants who elected to exercise warrants to purchase 11,749,098 shares of common stock on a "cashless" basis under the terms of the warrants. The warrants had an exercise prices of $0.25 per share (10,590,750 gross shares), $0.35 per share (750,000 gross shares), and $1.00 per share (408,348 gross shares). The aggregate intrinsic value of the warrants exercised was $16,171,952 for the six months ended June 30, 2013.

 

Stock-based compensation expense related to warrants for the three and six months ended June 30, 2013 was recorded in the condensed consolidated statements of operations as a component of selling, general and administrative expenses and totaled $9,587 and $514,364, respectively. There was no stock-based compensation expense related to warrants during the three and six months ended June 30, 2012. As of June 30, 2013, stock-based compensation expense related to warrants of $664,724 remains unamortized, including $87,884 which is being amortized over the weighted average remaining period of 2.3 years.  The remaining $576,840 is related to a performance based warrant where vesting is currently deemed to be improbable and no amount is being amortized.

 

A summary of the stock warrant activity during the three months ended June 30, 2013 is presented below:

 

          Weighted Average     Weighted Average Remaining        
    Number of     Exercise     Life     Intrinsic  
    Warrants     Price     In Years     Value  
                         
Outstanding, January 1, 2013     592,846     $ 3.01              
Granted     13,955,023       0.28              
Exercised     (11,749,098 )     0.28              
Forfeited     -       -              
Outstanding, June 30, 2013     2,798,771     $ 0.83       4.3     $ 2,695,729  
                                 
Exercisable, June 30, 2013     2,518,771     $ 0.58       4.4     $ 2,695,729  

 

The following table presents information related to stock warrants at June 30, 2013:

 

      Warrants Outstanding     Warrants Exercisable  
      Weighted           Weighted     Weighted Average        
Range of     Average     Outstanding     Average     Remaining     Exercisable  
Exercise     Exercise     Number of     Exercise     Life     Number of  
Price     Price     Warrants     Price     In Years     Warrants  
                                 
$ 0.25 - $0.35     $ 0.25       2,205,925     $ 0.25       4.6       2,205,925  
$ 0.36 - $3.00       2.91       562,846       2.91       3.2       312,846  
$ 3.01 - $4.95       4.95       30,000       -       -       -  
        $ 0.83       2,798,771     $ 0.58       4.4       2,518,771  

 

Services Contributed

 

Effective January 1, 2013, an executive officer of the Company waived payment for services contributed during 2013. As a result, the Company imputed the value of the services contributed and recorded salary expense of $87,500 and $175,000 for the three and six months ended June 30, 2013, respectively, with a corresponding credit to stockholders’ deficiency.